MCM
ALNY icon

MAI Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

MAI Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
1,281
+72
+6% +$21.7K ﹤0.01% 1445
2026
Q1 		$400K Buy
1,209
+762
+170% +$259K ﹤0.01% 1119
2025
Q4 		$178K Sell
447
-2
-0.4% -$885 ﹤0.01% 1358
2025
Q3 		$205K Sell
449
-39
-8% -$15.9K ﹤0.01% 1260
2025
Q2 		$159K Buy
488
+41
+9% +$11.3K ﹤0.01% 1284
2025
Q1 		$121K Buy
447
+3
+0.7% +$771 ﹤0.01% 1323
2024
Q4 		$105K Buy
+444
New +$117K ﹤0.01% 1415

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's ALNY Position: Q2 2026 in Review

MAI Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 6% in Q2 2026, buying an estimated $21.7K and bringing the position to 1,281 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

MAI Capital Management first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $400K in Q1 2026. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • MAI Capital Management held 1,281 shares of Alnylam Pharmaceuticals worth $386K as of Q2 2026.
  • MAI Capital Management bought 72 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $21.7K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1445 holding.
  • MAI Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • MAI Capital Management's Alnylam Pharmaceuticals position peaked at $400K in Q1 2026.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.